Skip to main content

Table 1 Synoptic view of the clinical articles

From: Critical appraisal of the role of volumetric modulated arc therapy in the radiation therapy management of breast cancer

Ref. # Authors Number of patients Type of treatment Median follow-up Toxicity
[11] Scorsetti et al. 50 SIB, 40.5Gy to whole breast and 48Gy to tumor bed 12 months Skin: Max G3 (1 case)
No other toxicity
[12] De Rose et al. 144 SIB, 40.5Gy to whole breast and 48Gy to tumor bed 37 months Skin max G3 (1 case)
Lung: max G1 (36 cases)
No other toxicity
[13] Riou et al. 9 APBI, 40 Gy in 4Gy fractions twice a day over 5 days. 26 months Acute: Max G1
Late: Max G1
(inclusive of skin, pneumonitis,pain, oedema)
[14] Kim et al. 31 VMAT with nodal involvement (internal mammary chain) 25.2 months Late max G2
No cardiac toxicity
[15] Lauche et al. HT: 31
VMAT: 42
SIB. Tumor bed: 63.2-63.8Gy; whole breast: 52.2Gy; supraclavicular nodes: 50.4Gy; internal mammary chain nodes: 52.2Gy Not explicitly reported.
3 months assumption from toxicity assessment statement
Skin: Max G3 (5% of patients, irrespective of technique)
Oesophagus: Max G2 (35-40%)
No lung toxicity
[16] Fiorentino et al. 16 patients SIB for synchrounous bilateral breast.
50Gy in 25 fractions to the whole breast, 60Gy to the tumor bed.
24 months No G3 of any type
Max G2 acute or late skin toxicity
Max G1 acute dysphagia.
  1. HT helical tomotherapy, VMAT volumetric modulated arc therapy, APBI accelerated partial breast irradiation, SIB simultaneous integrated boost